Delivery Order SPE2DB24D1205-SPE2DB25FCSWN

Award Date 1/8/25
Potential Completion Date 1/30/25
Potential Value $4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,085.52 Firm Fixed Price Delivery Order is for the supply of VEKLURY 100 mg vials, a prescription medication used to treat COVID-19. The contract has an ultimate completion date of November 8, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,924.40 firm fixed-price delivery order is for the supply of 100 mg vials of the antiviral drug Veklury. The award has an ultimate completion date of February 7, 2025 and is not designated as a set-aside contract. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The contract is a firm fixed price delivery order valued at $2,042.76 for the delivery of VEKLURY 100 MG VIALS. The contract has a completion date of February 22, 2024. Amerisourcebergen Drug Corp serves as a prime contractor providing a wide range of pharmaceutical...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corporation's Corporate Office division. The contract, valued at $27,236.80, is for the supply of VEKLURY 100 mg vials, a critical pharmaceutical product. This order is placed under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, which enables the government to...
The Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order contract worth $27,236.80 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide VEKLURY 100 MG VIALS. This delivery order is part of a larger indefinite delivery contract (IDC) awarded by DLA to Amerisourcebergen Drug Corp, with a potential value of up to $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary contract vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,809.20 firm fixed-price delivery order is for the supply of Veklury (Remdesivir) 100 mg vials, a medication used to treat COVID-19. The contract has an ultimate completion date of August 14, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This contract award, valued at $34,017.00, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Veklury (Remdesivir) 100 mg vials, a critical medication used in the treatment of COVID-19. The contract has a completion date of October 7, 2021 and utilizes a Firm Fixed Price pricing structure. AmerisourceBergen Drug Corp is a subsidiary of the parent company, Cencora, Inc., which holds a significant...
This federal contract award, with a ceiling value of $13,618.40, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the delivery of VEKLURY 100 MG VIALS, a pharmaceutical product. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA, valued up to $999,999,999.00 through December 31, 2025. This IDC serves as a primary vehicle for Amerisourcebergen to...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,401.70 firm fixed-price delivery order is for the supply of Veklury (Remdesivir) 100 mg vials, a critical medication used in the treatment of COVID-19. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., which serves as the...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,754.64, is for the supply of Veklury (Remdesivir) 100 mg vials, a critical medication used to treat COVID-19. The contract is a firm fixed-price delivery order with a completion date of February 26, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC)...
  • SPE2DB24D1205
    Indefinite Delivery Contract
  • SPE2DB24D1205-SPE2DB25FCSWN
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,962.20 fixed-price delivery order contract is for the procurement of 100 mg vials of Veklury, a medication used to treat COVID-19. The contract has an ultimate completion date of January 30, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This contract award was not designated with a set-aside requirement, indicating open competition.

Generated 4/9/25, 9:47 AM